4 citations,
February 2022 in “PeerJ” Hair follicle stem cell transplants can reverse liver cirrhosis by blocking harmful cell activation.
April 2017 in “Journal of Investigative Dermatology” HPH-15, a new compound, effectively reduces skin fibrosis in experiments without causing harm.
3 citations,
July 2022 in “Brain and Behavior” The HtrA1L364P mutation causes brain dysfunction and blood vessel damage.
18 citations,
February 2022 in “Cell Death Discovery” The study demonstrates that ECM1-modified hair follicle-derived mesenchymal stem cells (ECM1-HF-MSCs) can effectively treat liver cirrhosis by inhibiting the TGF-β/Smad signaling pathway, which is crucial in liver fibrosis. Using a mouse model of liver cirrhosis induced by CCl4, the research shows that ECM1-HF-MSCs improve liver function and reduce liver injury more effectively than naïve HF-MSCs. These modified cells migrate to the liver, express hepatocyte-specific markers, and significantly inhibit hepatic stellate cell activation. The findings suggest that ECM1-HF-MSCs offer a promising therapeutic approach for liver cirrhosis through genetic modification.
Higher TGF-β signaling may increase skin cancer risk in organ transplant recipients.